Literature DB >> 3059137

Inhibition of protein synthesis by a Vero toxin (VT2 or Shiga-like toxin II) produced by Escherichia coli O157:H7 at the level of elongation factor 1-dependent aminoacyl-tRNA binding to ribosomes.

T Ogasawara1, K Ito, K Igarashi, T Yutsudo, N Nakabayashi, Y Takeda.   

Abstract

A Vero toxin (VT2 or Shiga-like toxin II) from Escherichia coli O157:H7 was shown to inhibit protein synthesis in a rabbit reticulocyte lysate, but not in wheat germ or Ercherichia coli lysates. The toxin, VT2, inactivated 60S ribosomal subunits of rabbit reticulocytes. The site of inhibition of protein synthesis by VT2 was shown to be elongation factor 1-dependent aminoacyl-tRNA binding to ribosomes. VT2 did not affect Met-tRNAf binding to ribosomes, non-enzymatic binding of aminoacyl-tRNA to ribosomes, peptide bond formation or translocation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3059137     DOI: 10.1016/0882-4010(88)90054-x

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  14 in total

1.  Detection and production of verotoxin 1 of Escherichia coli O157:H7 in food.

Authors:  R D Weeratna; M P Doyle
Journal:  Appl Environ Microbiol       Date:  1991-10       Impact factor: 4.792

2.  Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications.

Authors:  Abhineet S Sheoran; Susan Chapman-Bonofiglio; Barrett R Harvey; Jean Mukherjee; George Georgiou; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

3.  Physicochemical and biological properties of purified Escherichia coli Shiga-like toxin II variant.

Authors:  D L MacLeod; C L Gyles; A Valdivieso-Garcia; R C Clarke
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

4.  Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1.

Authors:  F B Taylor; V L Tesh; L DeBault; A Li; A C Chang; S D Kosanke; T J Pysher; R L Siegler
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

5.  Prognostic model for time to achieve independent walking in children with Guillain-Barré syndrome.

Authors:  Peerada Chaweekulrat; Oranee Sanmaneechai
Journal:  Pediatr Res       Date:  2022-02-15       Impact factor: 3.756

6.  Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice.

Authors:  V L Tesh; J A Burris; J W Owens; V M Gordon; E A Wadolkowski; A D O'Brien; J E Samuel
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

7.  Minimum domain of the Shiga toxin A subunit required for enzymatic activity.

Authors:  J E Haddad; A Y al-Jaufy; M P Jackson
Journal:  J Bacteriol       Date:  1993-08       Impact factor: 3.490

8.  Vaccination with genetically modified Shiga-like toxin IIe prevents edema disease in swine.

Authors:  B T Bosworth; J E Samuel; H W Moon; A D O'Brien; V M Gordon; S C Whipp
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

9.  Bacterial endotoxin both enhances and inhibits the toxicity of Shiga-like toxin II in rabbits and mice.

Authors:  T J Barrett; M E Potter; I K Wachsmuth
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

Review 10.  Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections.

Authors:  J C Paton; A W Paton
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.